Imagine a world where millions of people no longer have to endure the relentless itching, swelling, and discomfort of chronic inducible urticaria (CIndU). This could soon become a reality, thanks to a groundbreaking development from Novartis. Their innovative therapy, remibrutinib, has just become the first treatment to successfully meet its primary endpoint in Phase III trials for CIndU, a condition affecting an estimated 29 million adults worldwide. But here's where it gets even more exciting: this isn't just a minor breakthrough—it's a potential game-changer for those suffering from this chronic skin condition.
On February 18, 2026, Novartis announced the positive topline results from the RemIND trial, a pivotal Phase III study evaluating the efficacy and safety of oral remibrutinib in CIndU. The trial demonstrated statistically significant and clinically meaningful outcomes, with complete responses achieved across the three most prevalent types of CIndU: symptomatic dermographism, cold urticaria, and cholinergic urticaria. But what does this mean for patients? It means that for the first time, there’s a targeted therapy on the horizon that could offer real relief, addressing a major unmet need in a condition that has long been challenging to treat.
Remibrutinib, a highly selective oral BTK inhibitor, works by blocking the BTK pathway involved in the release of histamine, a key driver of hives and swelling. This mechanism not only helps alleviate symptoms but also does so with a favorable safety profile, including no liver safety concerns—a critical factor for long-term use. And this is the part most people miss: while remibrutinib is already approved in the U.S. and China for chronic spontaneous urticaria (CSU) under the brand name Rhapsido®, its potential to treat CIndU could expand its impact significantly, offering hope to a broader patient population.
Angelika Jahreis, Global Head of Immunology Development at Novartis, highlighted the significance of these findings: “The positive RemIND trial results across three different types of CIndU underscore the potential of oral remibrutinib to achieve complete symptom relief for people living with CIndU and build on its recent FDA approval in CSU.” She further emphasized that remibrutinib could be the first targeted therapy to improve both spontaneous and inducible forms of chronic urticaria, helping to close a critical gap in care.
Novartis has already taken the next step by submitting a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for the treatment of symptomatic dermographism, the most common type of CIndU. In the coming months, the full data set will be shared with global health authorities, and the findings will be presented at major medical congresses. But here’s the controversial part: while this therapy shows immense promise, it also raises questions about accessibility and affordability. Will this treatment be available to all who need it, or will it remain out of reach for many due to cost or limited healthcare access? This is a discussion we need to have.
For those unfamiliar with CIndU, it’s a chronic skin condition characterized by hives and swelling triggered by external factors like pressure, sunlight, friction, heat, cold, or water. Unlike chronic spontaneous urticaria (CSU), which has no specific triggers, CIndU is highly unpredictable and can significantly disrupt daily life. Many patients cycle through antihistamines without finding adequate relief, and until now, there have been no approved targeted therapies. This is where remibrutinib steps in, offering a new ray of hope.
The RemIND trial (NCT05976243) was a global, multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy, safety, and tolerability of remibrutinib in adults with CIndU inadequately controlled by H1-antihistamines. The primary endpoint—the proportion of complete responders at Week 12—was assessed through provocation tests specific to the three CIndU subtypes. The results were clear: remibrutinib outperformed placebo, achieving significantly higher complete response rates.
But let’s not forget the bigger picture: while this is a major step forward, CIndU is just one of many immune-mediated conditions where remibrutinib is being investigated. Novartis is also exploring its potential in hidradenitis suppurativa (HS), food allergies, and other indications within their Neuroscience portfolio. This underscores the drug’s versatility and the broader impact it could have on immunology.
As we celebrate this milestone, it’s also important to acknowledge the challenges ahead. The journey from clinical trials to widespread availability is complex, involving regulatory approvals, manufacturing scalability, and patient access. And this is where we need your input: Do you think remibrutinib will live up to its promise? What concerns do you have about its accessibility? Let’s start a conversation in the comments below.
At Novartis, the mission is clear: to advance bold science that brings relief and hope to those living with autoimmune diseases. With a legacy of first-in-class innovation and a diverse, industry-leading pipeline, they’re committed to shaping the future of immunology. But the question remains: Will this future be inclusive, or will it leave some behind? That’s a debate worth having.
Disclaimer: This press release contains forward-looking statements, and actual results may vary. For more details, refer to Novartis AG’s Form 20-F filed with the U.S. Securities and Exchange Commission.
Reimagine medicine with Novartis. Visit their website and connect with them on social media to stay updated on their latest advancements. Together, we can shape a future where chronic conditions like CIndU are no longer a daily struggle.
